Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label, Single Arm Study to Investigate Anti-tumor Effect of Ixabepilone in Patients With Locally Recurrent or Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP After Failure of an Anthracycline and Taxanes.

NCT04796324 is registered in ClinicalTrials.gov with Allarity Therapeutics as lead sponsor.

NCT NCT04796324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04796324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label, Single Arm Study to Investigate Anti-tumor Effect of Ixabepilone in Patients With Locally Recurrent or Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP After Failure of an Anthracycline and Taxanes.
Lead sponsor
Allarity Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
March 1, 2021
Completion date
November 1, 2025
Enrollment
13 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer